MY126520A - A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same - Google Patents

A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same

Info

Publication number
MY126520A
MY126520A MYPI99002242A MYPI19992242A MY126520A MY 126520 A MY126520 A MY 126520A MY PI99002242 A MYPI99002242 A MY PI99002242A MY PI19992242 A MYPI19992242 A MY PI19992242A MY 126520 A MY126520 A MY 126520A
Authority
MY
Malaysia
Prior art keywords
reinforced
immunogen
producing
group
same
Prior art date
Application number
MYPI99002242A
Other languages
English (en)
Inventor
Ishikawa Toyokazu
Yoshii Horonori
Onishi Toshiyuki
Imagawa Tadashi
Ishibashi Masahide
Original Assignee
The Research Foundation For Microbial Disease Of Osaka Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation For Microbial Disease Of Osaka Univ filed Critical The Research Foundation For Microbial Disease Of Osaka Univ
Publication of MY126520A publication Critical patent/MY126520A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24163Methods of inactivation or attenuation by chemical treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI99002242A 1998-10-05 1999-06-03 A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same MY126520A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31976298 1998-10-05

Publications (1)

Publication Number Publication Date
MY126520A true MY126520A (en) 2006-10-31

Family

ID=18113906

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99002242A MY126520A (en) 1998-10-05 1999-06-03 A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same

Country Status (10)

Country Link
US (1) US6841374B1 (enExample)
EP (1) EP1057889B1 (enExample)
JP (2) JP4371343B2 (enExample)
KR (1) KR20010032699A (enExample)
CN (2) CN1618464A (enExample)
AU (1) AU743546B2 (enExample)
CA (1) CA2311336C (enExample)
MY (1) MY126520A (enExample)
TW (1) TWI227274B (enExample)
WO (1) WO2000020565A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
US7780027B2 (en) * 2007-02-08 2010-08-24 Michael Coady Axially stacked double barrel animal feeder system
SI2192917T1 (sl) 2007-08-28 2014-05-30 Baxter International Inc. Postopek za proizvodnjo virusnih cepiv
CA2710611C (en) * 2007-12-26 2016-12-20 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
CA2740598C (en) * 2008-11-17 2018-05-22 Mathura P. Ramanathan Antigens that elicit immune response against flavivirus and methods of using same
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
CN101792741A (zh) * 2010-04-07 2010-08-04 西北农林科技大学 表达jev免疫原基因的重组杆状病毒及其制备和应用
JP6963460B2 (ja) * 2016-10-27 2021-11-10 一般財団法人阪大微生物病研究会 たん白質の定量方法
JP6777837B1 (ja) * 2020-02-10 2020-10-28 花王株式会社 ヒトノロウイルス不活化評価法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6153227A (ja) 1984-08-23 1986-03-17 Biseibutsu Kagaku Kenkyusho:Kk 日本脳炎・豚パルボウイルス感染症混合生ワクチン
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
JPH07265093A (ja) * 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
NZ315357A (en) 1995-08-01 1999-08-30 Pasteur Merieux Serums Vacc Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
NZ503522A (en) 1997-08-28 2001-06-29 Us Army Attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine

Also Published As

Publication number Publication date
CN1618464A (zh) 2005-05-25
EP1057889A1 (en) 2000-12-06
WO2000020565A1 (en) 2000-04-13
AU4057899A (en) 2000-04-26
KR20010032699A (ko) 2001-04-25
AU743546B2 (en) 2002-01-31
JP2009225809A (ja) 2009-10-08
CA2311336C (en) 2007-01-02
TWI227274B (en) 2005-02-01
JP4371343B2 (ja) 2009-11-25
CN1287573A (zh) 2001-03-14
CN1160454C (zh) 2004-08-04
US6841374B1 (en) 2005-01-11
JP5095685B2 (ja) 2012-12-12
CA2311336A1 (en) 2000-04-13
EP1057889B1 (en) 2009-04-22
EP1057889A4 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
MY126520A (en) A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
GR3035712T3 (en) European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
TW289050B (enExample)
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
IL129286A0 (en) Reshaped human anti-HM 1.24 antibody
KR930703362A (ko) 병원체로부터 얻은 항원성 폴리오사이드로부터 유도된 올리고사이드
BR9608535A (pt) Agente virulento associado com a doença de suínos ignorada
RU97101084A (ru) Штамм streptococcus equi, микробиологически чистая культура, живая вакцина и способ ее получения
GR3035135T3 (en) Poultry vaccine containing infections bronchitis virus serotype 4/91.
ES533111A0 (es) Un metodo de preparar una vacuna viva
WO1994006913A3 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
IL95867A0 (enExample)
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
AU3830995A (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
SG47362A1 (en) Modified papilloma virus l2 protein and vlps formed thereform
IE830861L (en) Equine influenza vaccine.
AU3115189A (en) Live combination vaccine
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
CA2176929A1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
CA2015828A1 (en) Canine corona virus vaccine
PL346195A1 (en) Chicken anaemia virus (cav) of weakened patogenicity, vaccine for protecting poultry against cav and method of obtaining cav of weakened pathogenicity
BR9711138A (pt) Prepara-{es de herperv¡rus equino com prote-Æo mÚtua e m-todo de fazer e usar as mesmas
DK0809653T3 (da) Helicobacter pylori-antigen